Published in Cancer Res on November 17, 2010
Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas. Nat Neurosci (2011) 1.84
TRAIL on trial: preclinical advances in cancer therapy. Trends Mol Med (2013) 1.49
A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy. PLoS One (2015) 1.45
Mesenchymal stem cells engineered for cancer therapy. Adv Drug Deliv Rev (2011) 1.26
mTOR pathway in colorectal cancer: an update. Oncotarget (2014) 1.15
Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling. Oncotarget (2013) 1.05
Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1. Cell Death Differ (2013) 1.04
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget (2016) 1.02
Novel therapies in glioblastoma. Neurol Res Int (2012) 0.97
Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts. Cancer Lett (2011) 0.97
Stem cells as therapeutic vehicles for the treatment of high-grade gliomas. Neuro Oncol (2011) 0.96
Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors. Mol Cancer Ther (2012) 0.96
Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors. Oncogene (2012) 0.95
PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms. Theranostics (2014) 0.95
The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis. Cancer Lett (2013) 0.90
Strategies in gene therapy for glioblastoma. Cancers (Basel) (2013) 0.87
Systemic anticancer neural stem cells in combination with a cardiac glycoside for glioblastoma therapy. Stem Cells (2014) 0.87
Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors. Mol Ther (2012) 0.87
Alternative dosing of dual PI3K and MEK inhibition in cancer therapy. BMC Cancer (2012) 0.86
Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma. Stem Cells Transl Med (2014) 0.86
Mesenchymal stem cells secretome as a modulator of the neurogenic niche: basic insights and therapeutic opportunities. Front Cell Neurosci (2015) 0.86
Analysis of apoptosis methods recently used in Cancer Research and Cell Death & Disease publications. Cell Death Dis (2012) 0.85
A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy. Mol Cell Ther (2014) 0.85
Stem cells' guided gene therapy of cancer: New frontier in personalized and targeted therapy. J Cancer Res Ther (Manch) (2014) 0.85
Engineering toxin-resistant therapeutic stem cells to treat brain tumors. Stem Cells (2015) 0.85
Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384. Cancer Biol Ther (2014) 0.84
Identification of approved and investigational drugs that inhibit hypoxia-inducible factor-1 signaling. Oncotarget (2016) 0.84
Gene therapy for malignant glioma. Mol Cell Ther (2014) 0.83
Synergistic effects of targeted PI3K signaling inhibition and chemotherapy in liposarcoma. PLoS One (2014) 0.80
Targeting breast to brain metastatic tumours with death receptor ligand expressing therapeutic stem cells. Brain (2015) 0.80
Carbenoxolone enhances TRAIL-induced apoptosis through the upregulation of death receptor 5 and inhibition of gap junction intercellular communication in human glioma. Stem Cells Dev (2013) 0.79
Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors. Stem Cells (2015) 0.79
Evaluating the effect of therapeutic stem cells on TRAIL resistant and sensitive medulloblastomas. PLoS One (2012) 0.78
Imp2 regulates GBM progression by activating IGF2/PI3K/Akt pathway. Cancer Biol Ther (2015) 0.77
PET imaging of glioblastoma multiforme EGFR expression for therapeutic decision guidance. Am J Nucl Med Mol Imaging (2015) 0.77
Stem cell-based therapies for tumors in the brain: are we there yet? Neuro Oncol (2016) 0.77
Lyn kinase represses mucus hypersecretion by regulating IL-13-induced endoplasmic reticulum stress in asthma. EBioMedicine (2016) 0.75
Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas. Cytotherapy (2017) 0.75
NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5. Int J Oncol (2015) 0.75
Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma. Oncotarget (2017) 0.75
Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy. J Neurosurg (2013) 3.39
MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Res (2007) 2.90
Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res (2009) 2.74
Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci U S A (2009) 2.47
Performance of the red-shifted fluorescent proteins in deep-tissue molecular imaging applications. J Biomed Opt (2008) 1.93
Identification of genes conferring resistance to 5-fluorouracil. Proc Natl Acad Sci U S A (2009) 1.92
In vivo tracking of neural progenitor cell migration to glioblastomas. Hum Gene Ther (2003) 1.89
Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas. Nat Neurosci (2011) 1.84
TWIST1 promotes invasion through mesenchymal change in human glioblastoma. Mol Cancer (2010) 1.73
Molecular mechanism of chemoresistance by astrocyte elevated gene-1. Cancer Res (2010) 1.64
TRAIL on trial: preclinical advances in cancer therapy. Trends Mol Med (2013) 1.49
In vivo imaging of beta-galactosidase activity using far red fluorescent switch. Cancer Res (2004) 1.41
Astrocyte elevated gene-1: a novel target for human glioma therapy. Mol Cancer Ther (2010) 1.39
An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. Cell Rep (2013) 1.35
Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL. Neoplasia (2007) 1.33
Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc Natl Acad Sci U S A (2013) 1.33
Astrocyte elevated gene-1 promotes hepatocarcinogenesis: novel insights from a mouse model. Hepatology (2012) 1.32
Imaging of stem cell recruitment to ischemic infarcts in a murine model. Stroke (2004) 1.28
Fluorescence fluctuation analysis of Arabidopsis thaliana somatic embryogenesis receptor-like kinase and brassinosteroid insensitive 1 receptor oligomerization. Biophys J (2007) 1.23
Therapeutic stem-cells for cancer treatment: hopes and hurdles in tactical warfare. Lancet Oncol (2008) 1.20
Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. J Natl Cancer Inst (2011) 1.19
MDA-7/IL-24 plus radiation enhance survival in animals with intracranial primary human GBM tumors. Cancer Biol Ther (2008) 1.18
Brain cancer stem cells. J Mol Med (Berl) (2009) 1.18
Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide. Mol Cancer Ther (2008) 1.16
Malignant transformation eight years after removal of a benign epidermoid cyst: a case report. J Neurooncol (2006) 1.16
A novel method for imaging apoptosis using a caspase-1 near-infrared fluorescent probe. Neoplasia (2004) 1.11
Usefulness of L-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg (2005) 1.09
Accumulation of CD133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation. J Neurosurg (2010) 1.07
Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer? Future Oncol (2010) 1.07
Feasibility of in vivo imaging of fluorescent proteins using lifetime contrast. Opt Lett (2009) 1.07
Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts. Clin Cancer Res (2011) 1.06
A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells. Clin Cancer Res (2011) 1.06
Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma. Mol Ther (2010) 1.04
Therapeutic efficacy and fate of bimodal engineered stem cells in malignant brain tumors. Stem Cells (2013) 1.03
Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice. Stem Cells (2012) 1.02
A novel molecule integrating therapeutic and diagnostic activities reveals multiple aspects of stem cell-based therapy. Stem Cells (2010) 1.00
YB-1 bridges neural stem cells and brain tumor-initiating cells via its roles in differentiation and cell growth. Cancer Res (2011) 1.00
PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli. Cancer Res (2003) 0.97
Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models. Neoplasia (2013) 0.96
Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication. Cancer Res (2010) 0.95
Visualizing the dynamics of EGFR activity and antiglioma therapies in vivo. Cancer Res (2007) 0.93
Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics. Clin Cancer Res (2007) 0.92
Real-time multi-modality imaging of glioblastoma tumor resection and recurrence. J Neurooncol (2012) 0.91
Intra-arterial delivery of p53-containing adenoviral vector into experimental brain tumors. Cancer Gene Ther (2002) 0.91
Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors. J Virol (2012) 0.90
Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells. Stem Cells Transl Med (2012) 0.88
Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors. Mol Ther (2012) 0.87
Directed evolution of adeno-associated virus for glioma cell transduction. J Neurooncol (2009) 0.86
A first-generation multi-functional cytokine for simultaneous optical tracking and tumor therapy. PLoS One (2012) 0.86
The combination of adenoviral HSV TK gene therapy and radiation is effective in athymic mouse glioblastoma xenografts without increasing toxic side effects. J Neurooncol (2004) 0.86
Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects. Proc Natl Acad Sci U S A (2012) 0.86
Engineering toxin-resistant therapeutic stem cells to treat brain tumors. Stem Cells (2015) 0.85
Searching for a cure: gene therapy for glioblastoma. Cancer Biol Ther (2008) 0.85
Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma. Neurosurgery (2012) 0.85
Stem-cell based therapies for brain tumors. Curr Opin Mol Ther (2008) 0.83
High efficiency diffusion molecular retention tumor targeting. PLoS One (2013) 0.83
[Malignant lymphoma presented as left trigeminal neuralgia]. Rinsho Shinkeigaku (2009) 0.80
Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors. Stem Cells (2015) 0.79
Evaluating the effect of therapeutic stem cells on TRAIL resistant and sensitive medulloblastomas. PLoS One (2012) 0.78
Targeting Hypoxia-Inducible Factor 1α in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment. J Neuropathol Exp Neurol (2015) 0.78
Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma. J Neurooncol (2014) 0.77
In vivo neurometabolic profiling to characterize the effects of social isolation and ketamine-induced NMDA antagonism: a rodent study at 7.0 T. Schizophr Bull (2013) 0.76
Impairment of both apoptotic and cytoprotective signalings in glioma cells resistant to the combined use of cisplatin and tumor necrosis factor alpha. Clin Cancer Res (2004) 0.75
Adenovirus-mediated tissue-specific cytosine deaminase gene therapy for human hepatocellular carcinoma with different AFP expression levels. J Exp Ther Oncol (2002) 0.75
A rapid technique to evaluate the oxidative stability of a model drug. Drug Dev Ind Pharm (2007) 0.75